Business Context and Reporting Period
This Form 8-K filing by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) reports on the Annual Meeting of Shareholders held on June 4, 2015. The filing details the voting results for three proposals submitted to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Shareholders approved all three proposals presented at the meeting. Key voting statistics include:
- Shareholder Participation: 129,587,958 shares were present or represented by proxy out of 179,210,246 shares entitled to vote.
- Proposal 1 (Election of Directors): All seven nominees were elected. Votes ranged from approximately 61.6 million to 61.8 million "For" each director, with "Against/Withheld" votes ranging from approximately 2.8 million to 3.0 million. There were 64,953,082 broker non-votes.
- Proposal 2 (Ratification of Auditors): The appointment of Baker Tilly Virchow Krause, LLP was approved with 123,320,864 votes "For," 4,140,642 "Against," and 2,126,452 "Abstain."
- Proposal 3 (Reverse Stock Split Authorization): Shareholders approved an amendment to the Certificate of Incorporation to authorize a reverse stock split at a ratio between 1:2 and 1:10. Results were 100,326,670 "For," 28,158,312 "Against," and 1,102,974 "Abstain."
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors. The primary contingency noted is the authorization for a potential reverse stock split, the specific ratio of which is to be determined by the Board of Directors if deemed advisable.
Investor Verification Checklist
- Verify the actual implementation date and specific ratio of the authorized reverse stock split (1:2 to 1:10).
- Confirm the composition of the newly elected Board of Directors for the 2015-2016 term.
- Review the Definitive Proxy Statement filed on April 14, 2015, for detailed background on the proposals.
- Check subsequent filings for the official reduction in authorized shares following the reverse stock split.